Orchestra BioMed Holdings (OBIO) Non-Current Deffered Revenue (2020 - 2025)
Orchestra BioMed Holdings (OBIO) posted quarterly Non-Current Deffered Revenue of $8.7 million for Q3 2025, down 24.3% year-over-year from $11.4 million in Q3 2024, and down 9.5% quarter-over-quarter from $9.6 million in Q2 2025.
Powered by 
Analysis
Orchestra BioMed Holdings (OBIO) Non-Current Deffered Revenue (2020 - 2025) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Non-Current Deffered Revenue for 6 consecutive years, with $8.7 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Non-Current Deffered Revenue fell 24.3% year-over-year to $8.7 million; the TTM figure through Sep 2025 stood at $8.7 million (down 24.3% YoY), while the FY2024 annual figure was $11.0 million, down 26.36% from the prior year.
- Non-Current Deffered Revenue declined to $8.7 million in Q3 2025 per OBIO's latest filing, from $9.6 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $14.9 million in Q4 2023 and bottomed at $5.6 million in Q1 2021.
- Historically, Non-Current Deffered Revenue has averaged $9.8 million across 5 years, with a median of $10.8 million in 2025.
- Annual changes were most pronounced in 2023 — Non-Current Deffered Revenue soared 147.23% — and 2024, when it dropped 26.36%.
- Orchestra BioMed Holdings' Non-Current Deffered Revenue stood at $5.6 million in 2021, then surged by 133.98% to $13.1 million in 2022, then rose by 13.89% to $14.9 million in 2023, then fell by 26.36% to $11.0 million in 2024, then declined by 21.2% to $8.7 million in 2025.
- Business Quant data shows OBIO's Non-Current Deffered Revenue at $8.7 million in Q3 2025, $9.6 million in Q2 2025, and $10.8 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Orchestra BioMed Holdings | 322.25 Mn | 127.72 Mn | 63,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 8.66 Mn |
| Jun 30, 2025 | 9.57 Mn |
| Mar 31, 2025 | 10.75 Mn |
| Dec 31, 2024 | 10.99 Mn |
| Sep 30, 2024 | 11.44 Mn |
| Jun 30, 2024 | 12.65 Mn |
| Mar 31, 2024 | 13.87 Mn |
| Dec 31, 2023 | 14.92 Mn |
| Sep 30, 2023 | 13.85 Mn |
| Jun 30, 2023 | 13.50 Mn |
| Mar 31, 2023 | 13.20 Mn |
| Dec 31, 2022 | 13.10 Mn |
| Sep 30, 2022 | 5.60 Mn |
| Jun 30, 2022 | 5.60 Mn |
| Mar 31, 2022 | 5.60 Mn |
| Dec 31, 2021 | 5.60 Mn |
| Sep 30, 2021 | 5.60 Mn |
| Jun 30, 2021 | 5.60 Mn |
| Mar 31, 2021 | 5.60 Mn |
| Dec 31, 2020 | 5.60 Mn |